Esperion Therapeutics Inc

We remain bullish across all horizons as ESPR sits in a Stage 2 advance with a fresh higher-high/higher-low structure driven by a Lockout Rally above rising EMAs. The active Lockout Rally override validates a Buy Now posture despite near-term extension, favoring participation on shallow retracements into the 9/20 EMA support zone. Moderate distribution risk exists as EMAs flatten near recent highs, warranting vigilance for a shift in momentum.

• ↑Merger with Essence MergerCo enhances scale, capital, and efficiency.
• ↑30% of patients cannot tolerate statins, creating a large addressable market.
• ↓Trading suspended for the merger poses liquidity risk and uncertainty.